Company Filing History:
2 out of 3,559 
1 out of 112 Years Active: 2010-2017
Title: Michel Seve: Innovator in Diabetes Research
Introduction
Michel Seve is a notable inventor based in Grenoble, France. He has made significant contributions to the field of diabetes research through his innovative patents. With a total of 2 patents, his work focuses on antibodies and proteins that play crucial roles in insulin regulation.
Latest Patents
One of Michel Seve's latest patents is titled "Antibodies specific for ZNT8." This invention provides antibodies that specifically recognize an epitope selected from a group consisting of SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, and SEQ ID NO. 10. These antibodies are essential for research related to ZnT8. Another significant patent is "Protein specific to pancreatic beta cells in islets of Langerhans and applications thereof." This invention relates to the protein ZnT-8, which is specifically expressed in pancreatic beta cells. It includes a polynucleotide encoding this protein, which is involved in the maturation and exocytosis of insulin. The applications of this invention are vital for sorting and studying beta cells and for screening medicines that act on diabetes and hyperinsulinism.
Career Highlights
Throughout his career, Michel Seve has worked with prominent organizations such as the Commissariat à l'Énergie Atomique and Université Joseph Fourier. His work in these institutions has allowed him to advance his research and contribute to the scientific community.
Collaborations
Michel Seve has collaborated with various professionals in his field, including Alain Favier. These collaborations have enriched his research and led to significant advancements in diabetes-related innovations.
Conclusion
Michel Seve's contributions to diabetes research through his patents and collaborations highlight his role as an influential inventor. His work continues to impact the scientific community and offers promising avenues for future research in diabetes treatment.